title: Serum IL-33 level is a predictor of progression-free survival after chemotherapy.
abstract: This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemotherapy patients and healthy subjects, respectively. sIL-33 levels were 131.9 (95% CI 105.9-184.9) pg/mL, 95.1 (95% CI 70.8-140.2) pg/mL and 95.7 (95% CI 73.3-114.3) pg/mL in pre-chemotherapy patients, post-chemotherapy patients and controls, respectively. The sIL-33 level in pre-chemotherapy patients was significantly higher than that in both post-chemotherapy patients and controls (P < 0.001 and P < 0.001, respectively). There was no statistically significant difference between the sIL-33 levels in post-chemotherapy patients and controls (P > 0.05). PFS in patients with the decline extent > 30.1% (median PFS not reached) was statistically significant longer than that (median PFS 7 months, 95% CI 1.569 - 12.431) in patients with the decline extent ≤ 30.1% (P = 0.003). The decline extent of sIL-33 level (> 30.1%) was associated with longer PFS (P = 0.006). Distant metastasis was associated with the decline extent of sIL-33 level (P = 0.034). The decline extent of sIL-33 after chemoresistance could be regarded as a predictor of the PFS of GC patients.
authors.affiliation: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.|Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.|Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu Province, China.
authors.forename: Wenwei
authors.initials: W
authors.lastname: Hu
authors.affiliation: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.|Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.|Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu Province, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Wu
authors.affiliation: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.|Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.|Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu Province, China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
authors.forename: Zhuojun
authors.initials: Z
authors.lastname: Zheng
authors.affiliation: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
authors.forename: Quanqin
authors.initials: Q
authors.lastname: Xie
authors.affiliation: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Deng
authors.affiliation: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.|Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu Province, China.
authors.forename: Jingting
authors.initials: J
authors.lastname: Jiang
authors.affiliation: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
authors.forename: Changping
authors.initials: C
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D004358:Drug Therapy; D005260:Female; D006801:Humans; D000067596:Interleukin-33 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D016019:Survival Analysis
chemical_list: C506536:IL33 protein, human; D000067596:Interleukin-33
keywords: IL-33; chemotherapy; decline extent; gastric cancer; progression-free survival